If the Headache Lifts and the Patient Barely Felt Anything, What Did the Work?

A company pitch crossed my desk promising the benefit of psychedelics with the experience engineered out. The idea is to keep the neuroplasticity and lose the eight-hour session. This is not a fringe idea.

Delix Therapeutics has built a business around "psychedelics without the trip." Their lead compound is described as non-hallucinogenic in humans, with an FDA-cleared design for at-home use. Scientific American framed the program as a question: should next-generation psychedelics skip the trip?

That pitch only works if the subjective experience is a side effect rather than the mechanism. We do not know that it is.

Without the marketing, the scientific question is whether the acute subjective experience causes the durable benefit or merely accompanies it. If it causes it, a non-hallucinogenic analog is a different drug with a different job. If it merely accompanies it, the experience is a cost to be minimized, and the companies engineering it out are correct in their approach. For clinical decision-making, that difference matters because it changes what you should expect a compound to do.

The headache literature is where the “maybe not” signal is strongest. In the cluster-headache work, a low-dose psilocybin pulse regimen was tested in a randomized, double-blind, placebo-controlled trial at doses that produce minimal subjective effects, and a blinded extension found reduced attack frequency with repeat dosing. More directly, a secondary analysis across the migraine and cluster-headache trials reported that psilocybin’s effect on headache frequency was not related to the acute psychedelic effects or to measures of mental health (a conference abstract, so hold it accordingly). The most recent psilocybin migraine trial points the same way.

For headache, the benefit may run through a serotonergic or neuroplastic pathway that does not require the patient to have a meaningful experience. That is the strongest evidence for the 'skip the trip' position, and it comes from actual pain patients, not animal models. Clinically, the subjective intensity may be less important in headache treatment than in other conditions.

Then you turn to depression, and the picture flips. In treatment-resistant depression, the quality of the acute psychedelic experience predicted the therapeutic outcome: patients who had more of what the researchers called oceanic boundlessness improved more. The authors concluded that the quality of experience is a key mediator of long-term change.

That study is small and correlational. Correlation is not mechanism. Expectancy, functional unblinding, and the fact that people who feel more during a session may be primed to report more afterward all complicate the interpretation of the finding. Separating those confounds is the work of carefully reading a psychedelic trial. Still, the result points the opposite way from the headache data, so clinicians should be cautious about applying it broadly.

The answer is unlikely to be the same for every indication. A migraine is not a meaning-making problem. Treatment-resistant depression, trauma, and existential distress plausibly are. For those, the experience may be doing work that no molecule can shortcut. We do not have head-to-head trials to answer this.

There is a political economy here that matters. A pill with no facilitator, no monitored session, and no controlled-substance handling is cheaper to scale and easier to sell than a model that requires trained clinicians in the room for a full day. That does not make the psychoplastogen thesis wrong. It does mean the scientific question is entangled with a business model. The answer that is more profitable will get more funding, regardless of what the data say. I recommend watching for that when you read the next confident headline.

For now, I recommend not letting marketing decide the clinical question. When evaluating a compound or a claim, ask which condition the evidence actually addresses. Do not import a depression finding into a pain conversation or the reverse. When talking with a patient, do not promise that a gentler, less intense session will work as well. For their condition, it might not. Treat the intensity of the experience as a variable to study, not a bug to design out or a feature to guarantee.

Whether the experience is doing the clinical work, and what that asks of you when it is, is the kind of question I address in continuing education for clinicians.

That remains the open question. In depression research, the quality of the acute experience predicted the outcome, suggesting it matters. In headache trials, benefit did not track the intensity of the experience, which suggests it may not. The likeliest answer is that it depends on the condition being treated. For clinicians, the safest takeaway is to match the claim to the indication before deciding how much the experience matters.

Possibly, depending on what is being treated. In the psilocybin headache trials, reductions in attack frequency were not related to the strength of the acute psychedelic effects, so a muted experience did not necessarily mean a failed treatment. For mood and trauma, the evidence is more mixed, and a minimal experience may matter more there.

Unknown in humans for most conditions. Compounds engineered to retain neuroplastic effects without hallucinations show promise in animal models and early human safety trials. Still, there are not yet head-to-head efficacy trials against classic psychedelics for depression, PTSD, or chronic pain. Effective for one indication would not imply effective for all.

Not as an established practice. Some headache protocols deliberately use low, minimally psychedelic doses, but those are research regimens for specific conditions, not a general rule you can apply across diagnoses. Dose, subjective intensity, and benefit have not been cleanly separated for most uses, and psilocybin remains investigational or restricted depending on jurisdiction.

Peter H. Addy, PhD, LPC, LMHC, is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances. When a client acts on one of these headlines, our free guide, What to Do After Your Client Uses Psychedelics, walks through the ensuing conversation.